The 67th Annual Scientific Meeting of the American Headache Society wrapped up this weekend. From Thursday June 19 through Sunday June 22, at the Minneapolis Convention Center, physicians, researchers, psychologists, nurse practitioners, and more met and discussed the latest advances and innovations in headache medicine.

The four-day conference was full of presentations, engaging sessions, and continuing education opportunities. The following recap highlights are research published in the June 2025 issue of Headache, the magazine of the AHS. Abstracts submitted for the annual meeting are typically included in the most-current issue or as a supplement to the current issue.

Effect of Erenumab Versus Other Migraine Preventive Medications on Cardiovascular and Cerebrovascular Outcomes: A United States Claims Database-based Observational Cohort Study
  • Description: The goal of this study was to estimate the real-world risk of cardiovascular events among patients with migraines who were treated with erenumab and other preventive medications.
  • Result: Researchers found no difference in the risk of vascular events in patients treated with erenumab versus other anti-calcitonin gene-related peptide pathway monoclonal antibodies or onabotulinumtoxinA.

Association Between Migraine and Cerebral White Matter Hyperintensities in Middle-Aged and Older Individuals: A Cross-sectional Study Using the UK Biobank Cohort

  • Description: The study explored the association between migraines and white matter hyperintensities (WMH) in middle-aged and older patients.
  • Result: In the studied demographic, migraine is associated with a decreased WMH burden. 

Migraine and Spontaneous Coronary Artery Dissection: A Retrospective Case-control Study

  • Description: Researchers had the task of determining if migraine is independently associated with higher odds of spontaneous coronary artery dissection in a case-control study.
  • Result: A migraine and spontaneous coronary artery dissection association can be partly related to the connection between migraine and vascular comorbidities, like hypertension.

Serum Levels of Autotaxin Reveal Its Role as a Novel Biomarker of Migraine

  • Description: The study focused on determining the potential role of autotaxin in migraine by studying concentrations in serum between patients with episodic and chronic migraine compared to healthy controls, as well as the correlation of autotaxin with clinical outcomes, and other biomarkers.
  • Result: Researchers found that serum levels were significantly higher in patients with episodic/chronic migraines. Autotaxin correlates with clinical outcomes, calcitonin gene-related peptide, endothelial dysfunction, and inflammation biomarkers. 

Sex Differences in Pain, Suicidal Ideation, and Suicide Attempts in Patients with Migraine

  • Description: The study was designed to examine sex-specific associations between non-cephalic pain and suicidal ideation and suicide attempts among patients living with migraine.
  • Result: The prevalence of suicidal ideation and suicide attempts was higher in female patients than male patients among patients ages 20-59 years old. The differences diminished after the age of 60.

Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine: Results from the TANDEM Study

  • Description: This study evaluated the tolerability and safety of ubrogepant for the acute treatment of migraine in patients taking atogepant for the preventive treatment of episodic migraine.
  • Result: Researchers found the use of atogepant 60mg QD and ubrogepant 100mg PRN safe and well tolerated for the preventive treatment of episodic migraine and the acute treatment of migraine respectively. No new safety signals were identified.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.